Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. (“Globus” or the “Company”)(NYSE: GMED). Such investors are advised to contact DaniellePeyton at newaction@pomlaw.comor 646-581-9980, ext.7980.
https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg
The investigation concerns whether Globus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On August 13, 2024, in a filing with the U.S. Securities and Exchange Commission, Globus disclosed that “on July 16, 2024, Globus Medical, Inc. received a warning letter from the U.S. Food and Drug Administration (the ‘FDA’) following an inspection of our facilities in Audubon, Pennsylvania. In the warning letter, the FDA cited deficiencies in the response letters sent by the Company to the FDA following the Form 483, List of Investigational Observations, which was delivered to the Company in connection with the inspection that occurred from February 15, 2024 until March 7, 2024. The letter describes observed non-conformities in establishing and maintaining product complaint procedures, including complaint investigations, trending, risk reconciliation, and Medical Device Report (MDR) procedures including timely reporting, pertaining to the ExcelsiusGPS® robotic system.”
Following disclosure of the FDA’s warning letter, Globus’s stock price fell $5.73 per share, or 7.84%, to close at $67.32 per share on August 13, 2024.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980
https://c212.net/c/img/favicon.png?sn=DC15736&sd=2024-09-25
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-globus-medical-inc—gmed-302258857.html
SOURCE Pomerantz LLP
https://rt.newswire.ca/rt.gif?NewsItemId=DC15736&Transmission_Id=202409251558PR_NEWS_USPR_____DC15736&DateId=20240925
COMTEX_458164722/1005/2024-09-25T15:58:27